Tesofensine

Overview

Tesofensine is a small molecule, not a peptide — it has no amino-acid sequence and works centrally by inhibiting the reuptake of three neurotransmitters (dopamine, norepinephrine, and serotonin), which reduces appetite. It was originally developed for Parkinson's and Alzheimer's disease, where incidental weight loss redirected it toward obesity. A Phase 2 trial (TIPO-1) reported roughly 10% average body-weight loss over 24 weeks, but development has been limited by a cardiovascular safety signal (increases in blood pressure and heart rate). As of 2026 it is NOT FDA-approved in the US (it is approved in Mexico for obesity). Human efficacy beyond Phase 2 is not established in pivotal US trials.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Weight loss / obesity (Phase 2 human data; NOT FDA-approved; approved in some countries such as Mexico)
• Appetite suppression (marketed claim; based on the same Phase 2 data)
• Hypothalamic obesity / Prader-Willi syndrome with metoprolol (investigational; FDA orphan-drug designation only, not approval)

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• WHOOP — resting heart rate and HRV trend (a known cardiovascular safety signal)
• Labs/vitals — blood pressure monitoring if a clinician is overseeing use
• Smart scale — weight and body-fat % trend
• MyFitnessPal — calories and protein g/kg, given appetite suppression
• Subjective — daily mood, sleep, and appetite check-ins (monoamine activity can affect mood/sleep)

Sources & References

1. [1]Tesofensine — an overview (ScienceDirect Topics)
2. [2]Tesofensine — Saniona (developer pipeline)
3. [3]Effect of Tesofensine on Weight Reduction in Patients With Obesity — ClinicalTrials.gov NCT00394667